OTC Markets OTCQX - Delayed Quote USD

Cogstate Limited (COGZF)

0.7200

+0.0400

+(5.88%)

As of January 20 at 7:00:00 PM EST. Market Open.

Discover 3 ASX Penny Stocks With Market Caps Over A$100M

The Australian market is experiencing a cautious start to the year, with the ASX 200 expected to open slightly lower amid global economic uncertainties and currency fluctuations. Despite these broader market challenges, penny stocks continue to attract attention as viable investment opportunities. Though often seen as relics of past trading days, penny stocks represent smaller or newer companies that can offer significant value when underpinned by strong financials. In this article, we...

Simply Wall St. 19 days ago

GWAXY

COGZF
+5.88%
MAU.AX
Cogstate Limited's (ASX:CGS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Most readers would already know that Cogstate's (ASX:CGS) stock increased by 8.3% over the past three months. Given...

Simply Wall St. 20 days ago

COGZF
+5.88%
Discover ASX Penny Stocks To Watch In December 2024

The ASX200 has experienced a modest rise, with the IT sector leading gains and Health Care lagging behind. In this context, penny stocks—though an older term—still represent an intriguing investment area for those seeking opportunities in smaller or emerging companies. By focusing on firms with solid financials and growth potential, investors can uncover promising prospects among these lesser-known stocks.

Simply Wall St. last month

COGZF
+5.88%
OTTEF

PPG.AX
Returns At Cogstate (ASX:CGS) Are On The Way Up

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...

Simply Wall St. 2 months ago

COGZF
+5.88%
Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics

NEW YORK, October 29, 2024--Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader Cogstate to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others.

Business Wire 2 months ago

DASTF

DASTY

COGZF
+5.88%
Uncovering Opportunities: Acusensus And 2 Other ASX Penny Stocks

The Australian market remained flat over the last week but has risen 22% over the past year, with earnings forecasted to grow by 12% annually. Despite being considered an outdated term, penny stocks still represent a compelling investment area, especially for those seeking growth opportunities in smaller or newer companies. When these stocks are supported by strong financials, they can offer significant potential for returns; let's explore some examples that stand out for their balance sheet...

Simply Wall St. 2 months ago

ACE.AX

DSE.AX

COGZF
+5.88%
Cogstate Insider Ups Holding During Year

From what we can see, insiders were net buyers in Cogstate Limited's ( ASX:CGS ) during the past 12 months. That is...

Simply Wall St. 3 months ago

COGZF
+5.88%
Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer

Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Cogstate, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will use her

GlobeNewswire 3 months ago

COGZF
+5.88%
Cogstate Ltd (COGZF) Full Year 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges

Cogstate Ltd (COGZF) reports strong profit growth and strategic advancements despite a decline in sales contracts and future revenue projections.

GuruFocus.com 3 months ago

CGS.AX
Investors in Cogstate (ASX:CGS) have seen enviable returns of 326% over the past five years

Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...

Simply Wall St. 3 months ago

COGZF
+5.88%
Cogstate Full Year 2024 Earnings: EPS Beats Expectations

Cogstate ( ASX:CGS ) Full Year 2024 Results Key Financial Results Revenue: US$43.4m (up 7.4% from FY 2023). Net income...

Simply Wall St. 4 months ago

COGZF
+5.88%
Actinogen Medical stocks plummet after Phase IIa depression trial failure

Actinogen Medical’s stock dropped by 60% after the announcement that the MDD trial failed to meet its primary endpoint.

Clinical Trials Arena 5 months ago

CGS.AX
Cogstate Limited's (ASX:CGS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

It is hard to get excited after looking at Cogstate's (ASX:CGS) recent performance, when its stock has declined 9.9...

Simply Wall St. 5 months ago

COGZF
+5.88%
THREAD AND COGSTATE PARTNER TO SUPPORT CNS RESEARCH VIA NEXT GENERATION ECOA TECHNOLOGY AND LEADING COGNITIVE TESTING SOLUTIONS

Thread, a leading decentralized research and electronic clinical outcome assessment (eCOA) provider, today announced a collaboration with cognitive science leaders Cogstate Limited (ASX:CGS). The partnership combines Cogstate's best-in-class clinical and cognitive science solutions in digital assessment, endpoint data quality, remote assessments services, and deep experience in central nervous system (CNS) disorders with Thread's next-generation, proprietary no-code configurable eCOA platform in

PR Newswire 5 months ago

COGZF
+5.88%
IntelGenx reports preliminary data from Phase IIa Alzheimer’s disease trial

An analysis for each dose of the treatment indicated a significant improvement in cognition among patients.

Clinical Trials Arena 6 months ago

CGS.AX
Cogstate (ASX:CGS) Is Experiencing Growth In Returns On Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Simply Wall St. 8 months ago

COGZF
+5.88%
Cogstate (ASX:CGS) shareholders have earned a 42% CAGR over the last five years

For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...

Simply Wall St. 9 months ago

COGZF
+5.88%
Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Simply Wall St. 9 months ago

CGS.AX
Cogstate Limited (ASX:CGS) insiders have significant skin in the game with 50% ownership

Key Insights Significant insider control over Cogstate implies vested interests in company growth The top 3...

Simply Wall St. 10 months ago

CGS.AX
Are Cogstate Limited's (ASX:CGS) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Cogstate (ASX:CGS) has had a rough three months with its share price down 20%. However, the company's fundamentals look...

Simply Wall St. 10 months ago

CGS.AX

Performance Overview

Return	COGZF	S&P/ASX 200 [XJO]
YTD	+14.29%	+3.32%
1-Year	-18.18%	+12.75%
3-Year	-50.68%	+17.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cogstate Limited (COGZF)

Discover 3 ASX Penny Stocks With Market Caps Over A$100M

Cogstate Limited's (ASX:CGS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Discover ASX Penny Stocks To Watch In December 2024

Returns At Cogstate (ASX:CGS) Are On The Way Up

Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics

Uncovering Opportunities: Acusensus And 2 Other ASX Penny Stocks

Cogstate Insider Ups Holding During Year

Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer

Cogstate Ltd (COGZF) Full Year 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges

Investors in Cogstate (ASX:CGS) have seen enviable returns of 326% over the past five years

Cogstate Full Year 2024 Earnings: EPS Beats Expectations

Actinogen Medical stocks plummet after Phase IIa depression trial failure

Cogstate Limited's (ASX:CGS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

THREAD AND COGSTATE PARTNER TO SUPPORT CNS RESEARCH VIA NEXT GENERATION ECOA TECHNOLOGY AND LEADING COGNITIVE TESTING SOLUTIONS

IntelGenx reports preliminary data from Phase IIa Alzheimer’s disease trial

Cogstate (ASX:CGS) Is Experiencing Growth In Returns On Capital

Cogstate (ASX:CGS) shareholders have earned a 42% CAGR over the last five years

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Cogstate Limited (ASX:CGS) insiders have significant skin in the game with 50% ownership

Are Cogstate Limited's (ASX:CGS) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Performance Overview